Efficacy and safety of a new long-acting drug combination, trandolapril/verapamil as compared to monotherapy in primary hypertension

Blood Pressure

Volumn 9, Issue 2-3, 2000, Pages 140-145

  Karlberg, Bengt E ^a,c   Andrup, Mattias ^b   Odén, Anders ^d  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^b Knoll Läkemedel AB   (Sweden)

^c LINKÖPING UNIVERSITY   (Sweden)

^d NONE

Author keywords

Combination treatment; Efficacy; Primary hypertension controlled trial; Safety; Trandolapril; Verapamil

Indexed keywords

TRANDOLAPRIL; VERAPAMIL;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR RESPONSE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EDEMA; ERECTILE DYSFUNCTION; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART PALPITATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SLEEP DISORDER;

EID: 0034044386     PISSN: 08037051     EISSN: None     Source Type: Journal    
DOI: 10.1080/080370500453483     Document Type: Article

References (35)

1. Herbert P, Moser M, Mayer J, Hennekens CH. Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med 1993; 153: 578-81.
2. Hansson L. The benefits of lowering elevated blood pressure; a critical review of studies of cardiovascular morbidity and mortality in hypertension. J Hypertens 1996; 14: 537-44.
3. Moser M, Black HR. The role of combination therapy in the treatment of hypertension. Am J Hypertens 1998; 11: 73S-78S.
4. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-62.
5. Dooley M, Goa KL. Fixed combination verapamil/trandolapril. Drugs 1998; 56: 837-46.
6. Wathen LK, Nuorala KW, Wathen MW. Validation of an immunoradiometric assay to measure plasma levels of active renin. J Clin Lab Anal. 1991; 5: 284-92.
7. Nyström FH, Karlberg BE, Öhman KP. Serum angiotensin converting enzyme activity correlates positively with plasma angiotensin II: a population-based study of ambulatory blood pressure and the renin-angiotensin system. J Hum Hypertens 1997; 11: 301-6.
8. Swales JD. The cost of not treating hypertension. Blood Press 1999; 8: 198-9.
9. Chalmers J. The use of free and fixed drug combinations to improve hypertension control in our populations. Eur Heart J 1999; 20: 1060-1 (Editorial).
10. WHO-ISH Guidelines Sub-committee. 1999 WHO-ISH Guidelines for the management of mild hypertension. J Hypertens 1999; 17: 151-83.
11. Pool JL, Genrari J, Goldstein R, et al. Controlled multicenter study of the antihypertensive effects of lisinopril, hydrochlorothiazide, and lisinopril plus hydrochlorotiazide in the treatment of 394 patients with mild to moderate essential hypertension. J Cardiovasc Pharmacol 1987; 9 Suppl 1: 36-42.
12. Andersson OK for the Swedish Multicenter Group. Improved efficacy with maintained tolerability in the treatment of primary hypertension. Comparison between the felodipine-metoprolol combination tablet and monotherapy with enalapril. J Hum Hypertens 1999; 13: 55-60.
13. McTavish D, Sorkin EM. Verapamil. An uppdated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension. Drugs 1998; 38: 19-76.
14. Wiseman LR, McTavish D. Trandolapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in essential hypertension. Drugs 1994; 48: 71-90.
15. Scholze J, Zilles P, Compagnone D Verapamil SR and trandolapril combination therapy in hypertension. A clinical trial of factorial design. Br J Clin Pharmacol 1998; 45: 491-5.
16. De Quattro V, Lee D, Messerli F. Efficacy of combination therapy with trandolapril and verapamil SR in primary hypertension: a 4 × 4 trial design. Clin Exper Hypertens 1997; 19: 373-87.
17. Bakris GL, Weir MR, De Quattro V, McMahon FG. Effects of an ACE-inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998; 54: 1283-9.
18. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-301.
19. Pfeffer MA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992; 327: 669-77.
20. Chobanian AV, Haudenscild CC, Nickerson C, Susan S. Trandolapril inhibits atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Hypertension 1992; 20: 473-7.
21. Jacobsson LS, Persson K, Åberg G, Andersson RGG, Karlberg BE, Olsson AG. Aniatherosclerothic effects of the angiotensin-converting enzyme inhibitors captopril and fosinopril in the hypercholesterolemic minipigs. J Cardiovasc Pharmacol 1994; 24: 670-7.
22. Habib GB. Reappraisal of the heart rate as a risk factor in the general population. Eur Heart J 1999; 1 Suppl H: H2-H10.
23. Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A meta-anaiysis of 109 treatment studies. Am J Hypertens 1992; 5: 95-110.
24. Kjekshus J. Importance of heart rate in the determining beta-blocker efficacy in acute and long-term myocardial infarction intervention trials. Am J Cardial 1986; 57: 43F-49F.
25. Zuanetti G, Hernandez-Bernal F, Rossi A, Comeiro G, Paolucci G, Maggioni AP. Relevance of heart rate as a prognostic factor in myocardial infarction: the GISSI experience. Eur Heart J 1999; 1 Suppl H: H52-57.
26. Schneider M, Lerch M, Papiri M, et al. Metabolic neutrality of combined verapamil-trandolapril treatment in contrast to beta-blocker-low dose chlortalidone treatment in hypertensive type 2 diabetes. J Hypertens 1996; 14: 669-77.
27. Holzgreve H, Compagnone D, Zilles Pon behalf of the German Veratran Hypertension Study Group. Veratran SR/trandolapril combination therapy for the elderly hypertensive patient. J Human Hypertens 1999; 13: 61-7.
28. The Danish study group on verapamil in myocardial infraction. Verapamil in acute myocardial infarction. Eur Heart J 1984; 5: 516-28.
29. The Danish study group on verapamil in myocardial infarction. Effects of verapamil on mortality and major events after myocardial infarction (The Danish Verapamil Infarction Trial II - DAVIT II). Am J Cardiol 1990; 66: 779-85.
30. Laragh JH. Vasoconstriction-volume analysis for understanding and treating hypertension. The use of renin and aldosterone profiles. Am J Med 1973; 55: 261-8.
31. Kaplan NM. Renin profiles. The unfulfilled promises. JAMA 1977; 238: 611-13.
32. Alderman MH, Madhavan S. Ooi WL, et al. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991; 324: 1098-104.
33. Case DB. Wallace JM, Keim HJ, et al. Possible role of renin in hypertension as suggested by renin-sodium profiling and inhibition of converting enzyme. N Engl J Med 1977; 296: 641-6.
34. Adlin EV, Marks AD, Channick BJ. Spironolactone and hydrochlorothiazide in essential hypertension: blood pressure response and plasma renin activity. Arch Intern Med 1972; 130: 855-8.
35. Erne P, Bolli P, Bertel O, et al. Factors influencing the hypotensive effects of calcium antagonists. Hypertension 1983; 5 Suppl II: II97-II102.